AEON Biopharma’s (AEON) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of AEON Biopharma (NASDAQ:AEON) in a report published on Wednesday, Benzinga reports. They currently have a $6.00 price target on the stock.

AEON Biopharma Stock Performance

Shares of AEON opened at $1.40 on Wednesday. The firm’s fifty day simple moving average is $1.41 and its 200-day simple moving average is $6.24. AEON Biopharma has a twelve month low of $0.92 and a twelve month high of $17.17.

AEON Biopharma (NASDAQ:AEON) last posted its quarterly earnings results on Tuesday, May 14th. The company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.03. Sell-side analysts anticipate that AEON Biopharma will post -0.91 earnings per share for the current fiscal year.

Institutional Investors Weigh In On AEON Biopharma

A hedge fund recently raised its stake in AEON Biopharma stock. Vanguard Group Inc. lifted its holdings in shares of AEON Biopharma, Inc. (NASDAQ:AEON) by 261.8% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 758,992 shares of the company’s stock after buying an additional 549,207 shares during the period. Vanguard Group Inc. owned approximately 2.01% of AEON Biopharma worth $8,804,000 at the end of the most recent quarter. Institutional investors own 22.78% of the company’s stock.

AEON Biopharma Company Profile

AEON Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine.